Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IMPRiND

Financiado

Cerrado

Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases Sofia r...

Inhibiting Misfolded protein PRopagation in Neurodegenerative Diseases Sofia ref. 116060 Assemblies of tau and α-synuclein were shown to spread along interconnected neuronal networks suggesting broadly relevant therapeutic directions for Alzheimer’s and Parkinson’s disease. This requires a pre-clinical stage of develo... ver más

28/02/2022

UOXF

11M€

Presupuesto del proyecto: 11M€

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 20 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-02-28

IMI2-2015-07-02: IDENTIFICATION OF DRUGGABLE TARGETS... Specific Challenge:In Alzheimer’s Disease (AD) extracellular depositions of amyloid beta peptides (p...

I+D

Cerrada

0% 41% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

20 Participantes

UOXF

899.84K€ | Lider

CENTRO MEDICO LA SALUD GRUPO...

CNRS

327.00K€ | Participante

Eli Lilly

970.84K€ | Participante

Proyectos interesantes

PID2019-105017RB-I00

Medical Technol...

Biotechnology

290K€ Cerrado

NEUROFOLD

Medical Technol...

Data Science

100K€ Cerrado

PROTEASOME-AMYLOID

Medical Technol...

Data Science

173K€ Cerrado

Tau Seeding

Medical Technol...

Data Science

171K€ Cerrado

DIVE into AD

Medical Technol...

Data Science

190K€ Cerrado

PROFITS

Medical Technol...

Biotechnology

100K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 58 meses Fecha Inicio: 2017-04-07
Fecha Fin: 2022-02-28

Líder del proyecto

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UN... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 11M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Assemblies of tau and α-synuclein were shown to spread along interconnected neuronal networks suggesting broadly relevant therapeutic directions for Alzheimer’s and Parkinson’s disease. This requires a pre-clinical stage of development that has yet to be met. The scale of neurodegenerative disease burden in Europe calls for an unprecedented research effort that can only be achieved through collaboration between leading European laboratories and the pharmaceutical industry. To meet this ambition the IMPRiND consortium will synergistically accelerate progress to map and target critical steps in the propagation, proteostatic response and protection against misfolded α-synuclein and tau. Specifically we aim to (1) identify disease-relevant assemblies, imprint their biological properties in vitro and generate homogeneous populations to assay and interfere with their pathogenic effects; (2) develop and miniaturise assays to monitor secretion, uptake, clearance and oligomerisation using bimolecular fluorescence complementation of oligomeric species or transfer of untagged assemblies to fluorescently labelled fibril-naïve cells and measure markers of early proteotoxicity that are suitable for live imaging high content screens; (3) deliver robust validation assays for these molecular events in complex cellular systems with greater functional resemblance to the native milieu of the brain such as iPSC-based and organotypic cultures (4) standardise pathological readouts in animal models for in vivo validation of modifiers, correlate them with novel peripheral or in situ markers using microdialysis to accelerate the assessment of therapeutic interventions and relevance to humans, e.g. by transplantation of human iPSC neurons in animals; (5) assess toxicity and druggability of potential targets. IMPRiND will construct this entire pipeline to examine the prion-like properties of α-synuclein and tau and test their tractability against disease progression.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores